Similar articles

• Testicular function in prepubertal and pubertal male patients treated with cyclophosphamide for nephrotic syndrome.

  Penso J, Lippe B, Ehrlich R, Smith FG Jr. Penso J, et al. J Pediatr. 1974 Jun;84(6):831-6. doi: 10.1016/s0022-3476(74)80758-4. J Pediatr. 1974. PMID: 4826616 No abstract available.
• Gonadal function in males treated with cyclophosphamide for nephrotic syndrome.

  Hsu AC, Folami AO, Bain J, Rance CP. Hsu AC, et al. Fertil Steril. 1979 Feb;31(2):173-7. doi: 10.1016/s0015-0282(16)43818-5. Fertil Steril. 1979. PMID: 761678
• Postpubertal evaluation of gonadal function following cyclophosphamide therapy before and during puberty.

  Lentz RD, Bergstein J, Steffes MW, Brown DR, Prem K, Michael AF, Vernier RL. Lentz RD, et al. J Pediatr. 1977 Sep;91(3):385-94. doi: 10.1016/s0022-3476(77)81305-x. J Pediatr. 1977. PMID: 894406
• [Long-term effects of cyclophosphamide therapy in treatment of the "primary" nephrotic syndrome of childhood].

  Lama G. Lama G. Pediatria (Napoli). 1976 Jun 30;84(2):320-30. Pediatria (Napoli). 1976. PMID: 798171 Review. Italian. No abstract available.
• Alkylating agents in the treatment of nephrotic syndrome.

  West CD. West CD. Perspect Nephrol Hypertens. 1973;1 Pt 1:199-210. Perspect Nephrol Hypertens. 1973. PMID: 4620919 Review. No abstract available.